Recruiting
Phase 2
Alendronate for Osteonecrosis in Adults With Sickle Cell Disease
About this study
A prospective, single-arm, intervention study of oral alendronate in adults with sickle cell disease and osteonecrosis
- Condition
- Sickle Cell Disease, Sickle Cell Anemia, Osteonecrosis, Ischemic Necrosis, Avascular Necrosis
- Tested
- Alendronate Sodium
- Sponsor
- University of California, Davis
Who can join
- Age
- 18 to 80 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 7
- Minimum age: 18 years
- Maximum age: 80 years
- Study condition: Sickle Cell Disease, Sickle Cell Anemia, Osteonecrosis, Ischemic Necrosis, Avascular Necrosis
- Age 18-80 years with SCD (any genotype, confirmed by hemoglobin electrophoresis or high performance liquid chromatography)
- Ability to provide written informed consent
- Ability to lay on a dual-energy X-ray absorptiometry (DXA) scanner
- Negative urine pregnancy test for anyone of childbearing potential at study entry
Exclusion 5
- Pregnant women
- Adults unable to consent
- Individuals who are not yet adults (infants, children, teenagers)
- Prisoners
- Hospitalizations (for any cause) within 2 weeks of study entry
Where
1 site, 1 recruiting
UC Davis Comprehensive Cancer Center
Sacramento, California, United States
Contact
-
Leyla Y Teos, PhD
(916) 460-2749 lyteos@health.ucdavis.edu
Potential match only. Final eligibility is determined by the study team.